About Txinno
Txinno is a Healthcare company based in Yongin (South Korea) founded in 2020 by Chan-Sun Park and Seongjun Kim. Txinno has raised $5.95 million across 1 funding round from investors including Korea Investment Holdings, DSC Investment and Company K Partners. Its chief executive is Chan-Sun Park. Txinno offers products and services including Drug Development Platform and Pipeline Services. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Innate Immune System. Its legal entity in India is (μ£Ό)ν°μ¨λ Έλ°μ΄μ€μ¬μ΄μΈμ€ (U99999MH1977PLC010754). Its competitors include BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys and 5 more; 7 of its 10 listed competitors have raised funding.
Company details
Developer of therapeutics for the treatment of cancer. The company develops therapeutic agents focusing on the two characteristics, small-molecule compound targeting innate immunity in immunotherapy and RAS mutated anti-cancer drug in targeted cancer therapy.
- Headquarters Yongin, South Korea
- Founders Chan-Sun Park, Seongjun Kim
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website txinno.com
- Social LinkedIn
- Legal Name (주)티씨노바이오사이언스
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
- Total Equity Funding$5.95M (USD)
in 1 rounds
- Latest Funding Round$5.95M (USD), Series A
Aug 2021
- InvestorsKorea Investment Holdings
& 3 more
Associated legal entities of Txinno
Txinno operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of Txinno
Txinno offers a comprehensive portfolio of products and services, including Drug Development Platform and Pipeline Services.
Platform for developing small molecule anticancer drugs
Services for innovative drug pipelines in cancer treatment
Funding Insights of Txinno
Txinno has successfully raised a total of $5.95M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.95 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.95M
- Total Rounds 1
- Last Round Series A β $5.95M
- First Round $5.95M
(Aug 2021)
- Investors Count 4
All 1 funding rounds of Txinno with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | $5.95M | Series A | β | Company K Partners, DSC Investment | β |
4 investors in total: 4 institutional.
Investors in Txinno
Txinno has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Korea Investment Holdings, DSC Investment and Company K Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
Early-stage venture capital is invested primarily in South Korean startups. | 2012 | dscinvestment.com | Seoul, South Korea | |
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
Multiple sectors are invested in by Schmidt venture capital fund. | – | schmidt.kr | Seoul, South Korea |
Investor details for Txinno
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Txinno
2 people are tracked at Txinno (2 in leadership).
| Name | Role | Group |
|---|---|---|
Chan-Sun Park | CEO & Co-Founder | Leadership |
Seongjun Kim | Co-Founder & CTO | Leadership |
Complete people profiles for Txinno
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Txinno
2 dated milestones of Txinno across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Txinno is founded.
- Funding First funding round of $5.9M.
Competitors of Txinno
Txinno has 10 listed competitors in our database, 7 of them funded. They include BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. |
Detailed competitors of Txinno
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Txinno
The website of Txinno (txinno.com) receives about 1.3K visits a month.
- Monthly visits1.3K
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Txinno (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Txinno
Txinno was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Txinno is headquartered in Yongin, South Korea. It is registered at Yongin, Gyeonggi, South Korea.
Chan-Sun Park is the current CEO of Txinno. They have also founded this company.
Txinno is a funded company, having raised a total of $5.95M across 1 funding round to date. The company's 1st funding round was a Series A of $5.95M, raised on Aug 2021.
Developer of therapeutics for the treatment of cancer. The company develops therapeutic agents focusing on the two characteristics, small-molecule compound targeting innate immunity in immunotherapy and RAS mutated anti-cancer drug in targeted cancer therapy.
Txinno's top competitors include Moderna, BeiGene and Strand Therapeutics.
Txinno offers Drug Development Platform and Pipeline Services.
Txinno has 4 investors. Key investors include Korea Investment Holdings, DSC Investment, Company K Partners, and Schmidt.
Txinno operates through ,.